OpenAI is actively expanding its influence in the healthcare sector by developing artificial intelligence technologies aimed at enhancing medical research and patient management. The company is collaborating with industry leaders to leverage machine learning for improving diagnostics and treatment options, indicating a significant shift towards integrating AI in healthcare practices.

The FDA is exploring the use of AI, specifically through discussions with OpenAI, to expedite the drug approval process. This initiative, led by the FDA's first AI officer, aims to modernize regulatory reviews, although concerns about AI reliability and proper data training persist.